Breaking News Instant updates and real-time market news.

SFM

Sprouts Farmers Market

$22.02

1.14 (5.46%)

, DDC

Dominion Diamond

$9.92

1.1 (12.47%)

21:15
03/19/17
03/19
21:15
03/19/17
21:15

On The Fly: Top five weekend stock stories

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Private equity-backed grocery chain Albertsons held preliminary merger talks with Sprouts Farmers Market (SFM) in recent weeks, according to sources quoted by Bloomberg. Elsewhere in M&A, Washington Companies announced a bid for Dominion Diamond (DDC) but said talks have stalled over Dominion's refusal to open its books, though the diamond miner soon countered that Washington has itself refused to comply with standard negotiation agreements. Meanwhile, the Wall Street Journal reported Friday that activist investor Elliott Management is pushing Dutch paint maker Akzo Nobel (AKZOY) to consider a sale to PPG (PPG), but only at a higher price than the company's previous offer. 2. This weekend's American College of Cardiology conference brought a number of clinical updates from major drugmakers, with Amgen (AMGN), Abbott (ABT), Abiomed (ABMD) and others sharing their latest data. Separately, Array BioPharma (ARRY) said it pulled its FDA application for binimetinib in a rare subset of skin cancer. 3. Disney's (DIS) "Beauty and the Beast," the latest in a string of live-action remakes from the company, topped box offices with a record-breaking $170M launch in the U.S. alongside $180M from international markets. 4. Valeant (VRX) disclosed Friday that noted investor Bill Ackman and his Pershing Square colleague Stephen Fraidin won't seek reelection to the drugmaker's board, with the company explaining that "Ackman and Fraidin made this decision in light of the sale by Pershing Square and affiliated entities of all [Valeant] shares held by them and in order to dedicate more time to other Pershing Square portfolio companies and investment opportunities." 5. Welbilt (WBT) and Apple (AAPL) saw positive calls in Barron's, while GrubHub (GRUB) and Canada Goose (GOOS) were discussed negatively.

SFM

Sprouts Farmers Market

$22.02

1.14 (5.46%)

DDC

Dominion Diamond

$9.92

1.1 (12.47%)

PPG

PPG

$104.49

0.87 (0.84%)

AKZOY

AkzoNobel

$27.25

0.47 (1.76%)

AMGN

Amgen

$168.61

-11.5 (-6.39%)

ABT

Abbott

$45.19

0.21 (0.47%)

ABMD

Abiomed

$123.97

1.06 (0.86%)

ARRY

Array BioPharma

$10.56

-0.18 (-1.68%)

DIS

Disney

$111.76

0.05 (0.04%)

VRX

Valeant

$11.03

-0.17 (-1.52%)

WBT

Welbilt

AAPL

Apple

$139.99

-0.7 (-0.50%)

GRUB

GrubHub

$34.33

-0.18 (-0.52%)

GOOS

Canada Goose

$17.23

1.15 (7.15%)

  • 20

    Mar

  • 20

    Mar

  • 21

    Mar

  • 27

    Mar

  • 25

    May

  • 20

    Jun

  • 30

    Jun

  • 19

    Jul

SFM Sprouts Farmers Market
$22.02

1.14 (5.46%)

02/01/17
OTRG
02/01/17
UPGRADE
OTRG
Mixed
Sprouts Farmers Markets upgraded to Mixed from Negative at OTR Global
OTR Global changed its view on Sprouts Farmers Markets to Mixed following checks that indicate orders improved slightly in Q4 due to promotions.
01/27/17
WOLF
01/27/17
DOWNGRADE
WOLF
Peer Perform
Sprouts Farmers Markets downgraded to Peer Perform at Wolfe Research
02/27/17
RBCM
02/27/17
NO CHANGE
RBCM
Sprouts Farmers Markets fiscal 2017 guidance conservative, says RBC Capital
After Sprouts reported stronger than expected results, RBC Capital analyst William Kirk says that the company's fundamentals continue to be strong. He thinks that the company's guidance is "beatable," partly due to easing comps and lessening cannibalization, along with the contribution of the company's new stores to comp increases. Kirk remains upbeat on the company's fundamentals and keeps an Outperform rating on the shares.
02/02/17
FBCO
02/02/17
NO CHANGE
Target $23
FBCO
Outperform
Re-inflation to alleviate Sprouts Farmers Markets pressure, says Credit Suisse
Credit Suisse analyst Edward Kelly says that while short-term caution is certainly warranted given accelerating produce deflation and a tough overall competitive environment, he thinks Sprouts Farmers Markets' Q4 will eventually result in an attractive opportunity. The analyst believes the stock may be the most leveraged to re-inflation at this point, as comps should see relief when pricing firms, margin pressure should moderate as industry promotions begin to ease, and the valuation has upside given it is likely to remain a growth story. He reiterates an Outperform rating and $23 price target on the shares.
DDC Dominion Diamond
$9.92

1.1 (12.47%)

09/21/16
LEHM
09/21/16
UPGRADE
Target $11.4
LEHM
Overweight
Dominion Diamond upgraded to Overweight from Equal Weight at Barclays
Barclays analyst David Butler upgraded Dominion Diamond to Overweight with an $11.40 price target.
06/13/16
RBCM
06/13/16
DOWNGRADE
Target $11
RBCM
Sector Perform
Dominion Diamond downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Des Kilalea downgraded Dominion Diamond to Sector Perform with an $11 price target.
PPG PPG
$104.49

0.87 (0.84%)

03/09/17
BARD
03/09/17
NO CHANGE
BARD
PPG negotiations with AkzoNobel likely ongoing, says Baird
Baird said PPG's (PPG) negotiations with AkzoNobel (AKZOY) are likely ongoing despite Akzo's rejection. The firm's analyst believes potential anti-trust issues and fluid negotiation between the companies will likely result in an elongated timeline for any deal to close.
03/15/17
ATLE
03/15/17
UPGRADE
Target $125
ATLE
Overweight
PPG upgraded to Overweight from Neutral at Atlantic Equities
Atlantic Equities analyst Colin Isaac upgraded PPG to Overweight and raised his price target for the shares to $125 from $110.
03/10/17
RHCO
03/10/17
NO CHANGE
RHCO
PPG likely to continue pursuit of AkzoNobel, says SunTrust
After AkzoNobel,(AKZOY) rejected a bid by PPG (PPG), SunTrust analyst James Sheehan says he expects PPG to continue pursuing the deal, given what he sees as the "strong strategic rationale" for the transaction. He says that PPG's valuation is attractive and he keeps a Buy rating on the stock.
03/09/17
WELS
03/09/17
DOWNGRADE
WELS
Market Perform
PPG downgraded to Market Perform from Outperform at Wells Fargo
AKZOY AkzoNobel
$27.25

0.47 (1.76%)

03/10/17
SBSH
03/10/17
UPGRADE
SBSH
Buy
AkzoNobel upgraded to Buy from Neutral at Citi
Citi analyst Thomas Wrigglesworth upgraded AkzoNobel to Buy saying the company's review of strategic options for the Special Chemicals business is an unexpected catalyst. The analyst raised his price target for the shares to EUR 90 from EUR 68.
03/14/17
BOFA
03/14/17
UPGRADE
BOFA
Neutral
AkzoNobel upgraded to Neutral from Underperform at BofA/Merrill
AMGN Amgen
$168.61

-11.5 (-6.39%)

03/17/17
NEED
03/17/17
NO CHANGE
Target $25
NEED
Strong Buy
Needham calls Esperion selloff on Amgen data 'counter-intuitive'
Needham analyst Chad Messer believes the selloff in shares of Esperion Therapeutics (ESPR) based on Amgen's (AMGN) Repatha's data is "counter-intuitive." The fact that there was a statistically significant benefit confirms that LDL reductions prevent heart attacks and strokes, Messer tells investors in a research note. Bempedoic acid will likely be priced more in line with other oral cholesterol therapies, which makes the value debate for PCSK9 drugs a positive for Esperion, not a negative, the analyst contends. The analyst keeps a Buy rating on Esperion with a $25 price target.
03/17/17
JPMS
03/17/17
NO CHANGE
JPMS
Overweight
Amgen data do not justify Medicines selloff, says JPMorgan
JPMorgan analyst Jessica Fye believes today's cholesterol data from Amgen (AMGN) do not justify the downward move in shares of The Medicines Co. (MDCO). The analyst sees a "clear clinical benefit" from Amgen's Repatha, which she thinks support the likelihood of clinical success and value for Medicines' inclisiran. The analyst remains comfortable with her 70% probability of success and $1.6B peak sales forecast for inclisiran. Fye keeps an Overweight rating on Medicines and believes the 18% selloff today is overdone.
03/17/17
PIPR
03/17/17
NO CHANGE
PIPR
Overweight
Amgen weakness a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer recommends using today's weakness in shares of Amgen as a buying opportunity. The analyst believes Amgen can still turn Repatha into a $5B-plus product and he reiterates an Overweight rating on the shares.
03/17/17
OPCO
03/17/17
NO CHANGE
OPCO
Outperform
Amgen oversold on cholesterol data, says Oppenheimer
Oppenheimer analyst Leah Rush Cann says shares of Amgen are oversold after the FOURIER study of Repatha in patients with cardiovascular disease met its key endpoint. The risk reduction grew to 25% after one year on Repatha therapy, which is a "very important result," Cann tells investors in a research note. She believes the current stock price reflects little to no sales of Repatha through 2020. The analyst has an Outperform rating on Amgen, which is trading down 6% to $168.68.
ABT Abbott
$45.19

0.21 (0.47%)

03/14/17
03/14/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Corning (GLW) downgraded to Neutral from Buy at Goldman with analyst Doug Clark citing valuation with the stock up 33% since his upgrade back in April of 2016. The analyst keeps a $29 price target for the shares. 2. Amphastar (AMPH) downgraded to Outperform from Strong Buy at Raymond James with analyst Elliot Wilbur saying he sees an increased near-term risk profile following indications from FDA that Amphastar may have to withdraw its epinephrine product. 3. Abbott (ABT) downgraded to Market Perform from Outperform at BMO Capital. 4. GGP (GGP) downgraded to Neutral from Buy at UBS with analyst Jeremy Metz saying he does not see headwinds in the sector easing in the short term and cut his price target for GGP shares to $25 from $28. 5. Harmonic (HLIT) downgraded to Hold from Buy at Drexel Hamilton. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/01/17
RAJA
03/01/17
NO CHANGE
RAJA
Market Perform
Alere filing delay should not be surprise, says Raymond James
Raymond James analyst Nicholas Jansen says that while the annual filing delay is not a headline Alere (ALR) shareholders wanted to see given the company's current battle with Abbott (ABT), the revision just relates to timing, not "bad revenue," and is immaterial in totality relative to a $2.5B revenue base. Alere's annual filing was unlikely to include a full remediation of internal control weakness, so this issue, while disappointing, should not be a surprise, Jansen tells investors in a research note. He keeps a Market Perform rating on the shares. Alere in early trading is down 3%, or $1.27, to $37.03.
01/23/17
COWN
01/23/17
NO CHANGE
Target $48
COWN
Outperform
Abbott valuation compelling and discount may not last long, says Cowen
Cowen analyst Joshua Jennings said Abbott's valuation is currently at a compelling discount, but that may not last long. He said the Abbott/St. Jude Medical combination has given him conviction the combined company can sustain greater than 5% organic growth and 12-15% earnings growth in 2018 to 2020. Jennings reiterated his Outperform rating and $48 price target on Abbott shares.
03/14/17
BMOC
03/14/17
DOWNGRADE
BMOC
Market Perform
Abbott downgraded to Market Perform from Outperform at BMO Capital
ABMD Abiomed
$123.97

1.06 (0.86%)

12/07/16
12/07/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Micron (MU) initiated with a Buy at Citi. 2. Owens Corning (OC) initiated with a Buy at Seaport Global. 3. Abiomed (ABMD) initiated with a Buy at Guggenheim. 4. ZELTIQ (ZLTQ) initiated with a Buy at Aegis. 5. Navient (NAVI) initiated with a Hold at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/07/16
GUGG
12/07/16
INITIATION
Target $150
GUGG
Buy
Abiomed initiated with a Buy at Guggenheim
Guggenheim analyst Christopher Pasquale initiated Abiomed with a Buy and a $150 price target.
12/06/16
GUGG
12/06/16
INITIATION
GUGG
Buy
Abiomed initiated with a Buy at Guggenheim
11/18/16
LEER
11/18/16
NO CHANGE
Target $140
LEER
Outperform
Abiomed remains on 'hyper-growth trajectory,' says Leerink
After hosting investor meetings with the company's CEO Mike Minogue, CFO Mike Tomsicek, and Director of IR Ingrid Goldberg, Leerink analyst Danielle Antalffy remains confident that Abiomed's fundamentals are intact, and the company remains on a "hyper-growth trajectory" with significant positive operating leverage. The analyst remains confident in a sustainable long-term "strong" double-digit growth trajectory built on a market-leading product, a large and still-expanding salesforce, and a "strong" foundation of clinical evidence. She reiterates an Outperform rating and $140 price target on the shares.
ARRY Array BioPharma
$10.56

-0.18 (-1.68%)

01/30/17
01/30/17
DOWNGRADE
Target $11

Market Perform
Array BioPharma downgraded to Market Perform on valuation at Leerink
As previously reported, Leerink analyst Michael Schmidt downgraded Array BioPharma to Market Perform from Outperform as he sees limited near-term upside drivers while the company's pipeline is now "fairly valued" following the recent run. Further, the analyst notes that key events, such as results of its COLUMBUS and NEMO Phase 3 trials are now in the rear-view mirror while value-driving catalysts appear limited over the next 12 months. Nonetheless, Schmidt raised his price target on the shares based on adjustments to his binimetinib/encorafenib forecast in melanoma and inclusion of estimates for selumetinib royalties in Neurofibromatosis.
02/03/17
JPMS
02/03/17
DOWNGRADE
Target $10
JPMS
Neutral
Array BioPharma downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Anupam Rama downgraded Array BioPharma to Neutral saying the shares are fully valued after rallying 24% year-to-date. The analyst raised his price target for the shares to $10 from $8.
01/17/17
PIPR
01/17/17
NO CHANGE
Target $15
PIPR
Overweight
Array BioPharma strength likely aided by M&A speculation, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff noted that Array BioPharma (ARRY) shares hit a 52-week high during Friday's trading, which he attributes to M&A speculation following Ariad's (ARIA) agreement to be acquired by Takeda (TKPYY). Tenthoff, who sees several business development opportunities for Array, reiterates his Overweight rating and $15 price target on the shares.
01/30/17
LEER
01/30/17
DOWNGRADE
LEER
Market Perform
Array BioPharma downgraded to Market Perform from Outperform at Leerink
DIS Disney
$111.76

0.05 (0.04%)

02/08/17
BARD
02/08/17
NO CHANGE
Target $960
BARD
Outperform
Baird sees Disney deal supporting Google's subscription growth
Baird analyst Colin Sebastian believes Alphabet's (GOOG, GOOGL) YouTube reported licensing agreement with Disney (DIS) represents a more aggressive push by the company into long-form/original video content. Recent reports suggest Disney has reached a licensing agreement with YouTube for its family of networks as part of a broader YouTube streaming offering to be announced later this year, Sebastian tells investors in a research note. With Disney possibly joining CBS (CBS), which Alphabet inked a deal with late last year, YouTube's live stream bundle could help accelerate the migration of offline ad-budgets toward digital platforms, the analyst contends. He believes such an acceleration would be a "key positive" and drive "material growth" in Google's subscription business. Sebastian has an Outperform rating on Alphabet with a $960 price target.
03/16/17
PIPR
03/16/17
NO CHANGE
Target $130
PIPR
Overweight
Piper more confident after seeing Disney's Beauty and the Beast
Piper Jaffray analyst Stan Meyers says he left a screening of Disney's Beauty and the Beast more confident in his $900M global box office forecast. The analyst admits the film's 68% Rotten Tomatoes score is an issue, but he believes limited competition over the next few weeks and the film's darker undertone to broaden the target audience should secure "strong staying power" after the opening. He expects the movie to open in the $130M-$140M range. Meyers keeps an Outperform rating on Disney.
03/14/17
03/14/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Buy from Neutral at Guggenheim with analyst Michael Morris upgraded saying that he still sees strong potential upside despite the stock's move off its lows as the company enters another expansion cycle for its film, consumer products and parks businesses. The analyst is more cautious on the Networks business, both for Disney and the broader industry, but thinks that is reflected already in Disney shares. Morris raised his price target on Disney shares to $128 from $118. 2. Dick's Sporting (DKS) upgraded to Outperform from Peer Perform at Wolfe Research. 3. Quest Diagnostics (DGX) upgraded to Conviction Buy from Buy at Goldman with analyst Isaac Ro saying the company should be a key beneficiary as the U.S. healthcare system shifts the cost burden to the individual and creates price transparency for the first time. 4. Olympic Steel (ZEUS) and Reliance Steel (RS) were upgraded to Outperform from Neutral at Macquarie, while Worthington (WOR) was upgraded to Neutral from Underperform. 5. Ethan Allen (ETH) upgraded to Strong Buy from Market Perform at Raymond James with analyst Budd Bugatch double upgrading the company saying sales comparisons get easier through 2017 while the retailer's remerchandising effort is behind it, thereby lowering the clearance markdowns. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/14/17
GUGG
03/14/17
UPGRADE
Target $128
GUGG
Buy
Disney upgraded to Buy from Neutral at Guggenheim
Guggenheim analyst Michael Morris upgraded Disney to Buy from Neutral saying that he still sees strong potential upside despite the stock's move off its lows as the company enters another expansion cycle for its film, consumer products and parks businesses. The analyst is more cautious on the Networks business, both for Disney and the broader industry, but thinks that is reflected already in Disney shares. Morris raised his price target on Disney shares to $128 from $118.
VRX Valeant
$11.03

-0.17 (-1.52%)

03/17/17
WELS
03/17/17
NO CHANGE
WELS
Underperform
Wells Fargo finds 'new significant negative' for Valeant
Wells Fargo analyst David Maris says the FDA's new guidance posted today on what is needed for generic Xifaxan is a "game changing development that makes it much easier for generics to show bioequivalence." The likelihood of Xifaxan generics entering the market in 2023 or earlier just "increased dramatically," Maris tells investors in a research note. He views today's guidance as a "new significant negative" for Valeant Pharmaceuticals. The stock is down 3c to $11.17 in late morning trading. Maris has an Underperform rating on Valeant with a $10-$13 price target range.
03/15/17
ADAM
03/15/17
NO CHANGE
Target $12
ADAM
Hold
Valeant price target lowered to $12 from $17 at Canaccord
Canaccord analyst Neil Maruoka lowered his price target on Valeant to $12 from $17 following the sale of Pershing Square's 27.2M share stake. The analyst stills sees the divesting of major assets as a challenge and the sale by Pershing as underscoring his concerns about the company's lower growth. Maruoka maintained his Hold rating on Valeant shares.
03/18/17
WELS
03/18/17
NO CHANGE
WELS
Underperform
Valeant management positive on new FDA guidelines, says Wells Fargo
Wells Fargo analyst David Maris said in a research note late Friday that Valeant Pharmaceuticals views the FDA's new guidance for generic Xifaxan as a positive. Management believes the guidelines may delay generics which may not have conducted their studies to be compliant with the new guidance, Maris told investors in a research note. The analyst earlier in the day Friday told investors that he views the FDA's guidance as a "game changing development that makes it much easier for generics to show bioequivalence." Maris called the news a "new significant negative" for Valeant. He says his initial read is not changed by Valeant management's view, but added that he will review the feedback with outside consultants and other industry sources to gain a broader perspective. Maris has an Underperform rating on Valeant, his firm's equivalent of a sell. Shares of Valeant closed yesterday down 17c to $11.03.
03/14/17
STFL
03/14/17
NO CHANGE
STFL
Valeant Pershing move to hurt sentiment but restructuring positive, says Stifel
After Valeant's top shareholder, Pershing Square, announced the offering of its 27.2M share stake in the company, Stifel analyst Annabel Samimy says that the transaction will hurt sentiment towards Valeant. However, the analyst continues to believe that the company's recent restructuring was an important, step that produced meaningful benefits for the company, and she says that it "remains committed to its $5B debt repayment target by early 2018." She keeps a Buy rating on the stock.
WBT Welbilt

AAPL Apple
$139.99

-0.7 (-0.50%)

03/17/17
PACS
03/17/17
NO CHANGE
PACS
Tax repatriation law could boost Apple stock, says Pacific Crest
Pacific Crest analyst Andy Hargreaves estimates that a law cutting tax rates on repatriated profits could enable Apple to significantly boost its dividend. The increased dividend, in turn, " could support a significantly higher share price for" Apple, even if iPhone growth stagnates following the release of the iPhone 8, the analyst stated. He keeps an Overweight rating on the stock.
03/15/17
RBCM
03/15/17
NO CHANGE
RBCM
Apple services business could produce positive catalysts, says RBC Capital
RBC Capital analyst Amit Daryanani says that Apple's services business can increase its gross margins by 40-60 basis points , accelerate its ARPU and "create a better valuation narrative" for the company. He raised its price target on Apple to $155 from $140, as he believes that the stock will be boosted by capital allocation and cash repatriation and the iPhone 8 cycle, as well as by the services tailwind. Daryanan keeps an Outperform rating on the shares.
03/13/17
UBSW
03/13/17
NO CHANGE
Target $151
UBSW
Buy
Apple comps get easier in coming quarters, says UBS
UBS analyst Steven Milunovich looked at the global growth of the premium smartphone market and said Apple grew in all regions except China, which is critical to his thesis. The analyst believes the March and June quarter comps get easier, especially in China, and reiterated his Buy rating and $151 price target on Apple shares.
03/09/17
CHLM
03/09/17
NO CHANGE
CHLM
Buy
iPhone 8 may have STMicroelectronics facial recognition tech, says Craig-Hallum
Craig-Hallum notes there has been speculation that perhaps there will be component shortages preventing Apple (AAPL) from launching the iPhone 8 in late September. The speculation has surrounded finger print sensors, AMOLD panels and now 3D sensing components, the firm says, pointing out that most believe STMicroelectronics (STM) could have 2 sensors in iPhone 8. Furthermore, Craig-Hallum thinks the latter could have a new facial recognition technology in Apple's upcoming smartphone as well. The firm believes STMicroelectronics has already started to produce and stockpile parts for the Apple 8 and does not expect any issues on its side. Craig-Hallum notes that Samsung (SSNLF) officials have stated they will also put facial recognition in the upcoming Galaxy 8, which should be supplied by STMicroelectronics. The firm has a Buy rating on STMicroelectronics' shares.
GRUB GrubHub
$34.33

-0.18 (-0.52%)

02/17/17
KEYB
02/17/17
INITIATION
KEYB
Overweight
GrubHub coverage resumed with an Overweight at KeyBanc
KeyBanc expects GrubHub to benefit as more food ordering shifts online. The firm says its checks on the company indicate that it has "overall lead-generation/delivery benefits." Target $45.
02/09/17
02/09/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Dynegy (DYN) downgraded to Sell from Hold at Deutsche Bank with analyst Abe Azar saying New England capacity prices dropped another 25%. The result is below consensus and is the second straight year with a 25% drop, Azar tells investors in a research note. He lowered his price target for Dynegy shares to $6 from $8. 2. Freeport McMoRan (FCX) reinstated with a Neutral from Overweight at JPMorgan with analyst Michael Gambardella downgrading the company following a period of restriction. The analyst does not see much upside in Freeport shares at current copper prices. 3. GrubHub (GRUB) downgraded to Neutral from Buy at Mizuho. 4. Panera Bread (PNRA) downgraded to Neutral from Buy at Longbow with analyst Alton Stump citing valuation and raised its price target to $260. 5. Cree (CREE) downgraded to Market Perform from Outperform at JMP Securities wiuth analyst Joseph Osha saying it is unlikely to approve the company's sale of its Wolfspeed business. The analyst finds it wise to assume that the sale to Infineon (IFNNY) is not going to occur. The increased capital spending to support Wolfspeed lowers Osha's 2017 free cash estimate for Cree by 20%. He now views the stock as fairly valued. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/09/17
MZHO
02/09/17
DOWNGRADE
MZHO
Neutral
GrubHub downgraded to Neutral from Buy at Mizuho
01/23/17
01/23/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Liberty Global (LBTYA) resumed with an Equal Weight at Morgan Stanley. 2. BioMarin (BMRN) and Incyte (INCY) were initiated with an Outperform at Credit Suisse. 3. GrubHub (GRUB) initiated with a Hold at Craig-Hallum. 4. Molson Coors (TAP) initiated with a Neutral at Credit Suisse. 5. Achaogen (AKAO) initiated with a Buy at Guggenheim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
GOOS Canada Goose
$17.23

1.15 (7.15%)

TODAY'S FREE FLY STORIES

GE

General Electric

$24.55

-0.2 (-0.81%)

06:09
08/21/17
08/21
06:09
08/21/17
06:09
Periodicals
Jeff Immelt becomes front-runner to head Uber, Recode says »

Former General Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

  • 02

    Oct

GS

Goldman Sachs

$222.15

0.73 (0.33%)

, C

Citi

$66.58

-0.02 (-0.03%)

06:08
08/21/17
08/21
06:08
08/21/17
06:08
Periodicals
Goldman Sachs receives approval to trade equities in Saudi Arabia, Reuters says »

Goldman Sachs (GS) has…

GS

Goldman Sachs

$222.15

0.73 (0.33%)

C

Citi

$66.58

-0.02 (-0.03%)

CS

Credit Suisse

$14.88

0.18 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

KOS

Kosmos

$6.91

0.16 (2.37%)

06:05
08/21/17
08/21
06:05
08/21/17
06:05
Hot Stocks
Kosmos announces admission to trading on London Stock Exchange »

Kosmos Energy is pleased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRV

ContraVir Pharmaceuticals

$0.60

0.0098 (1.66%)

06:03
08/21/17
08/21
06:03
08/21/17
06:03
Hot Stocks
ContraVir Pharmaceuticals issued new U.S. patent for expansion of cyclophilin »

ContraVir Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

T

AT&T

$37.37

-0.23 (-0.61%)

, TWX

Time Warner

$101.19

-0.42 (-0.41%)

06:03
08/21/17
08/21
06:03
08/21/17
06:03
Periodicals
AT&T's proposed Time Warner takeover reaches late-stage point, WSJ reports »

The review of…

T

AT&T

$37.37

-0.23 (-0.61%)

TWX

Time Warner

$101.19

-0.42 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

ADP

ADP

$104.41

-0.27 (-0.26%)

06:01
08/21/17
08/21
06:01
08/21/17
06:01
Hot Stocks
ADP board rejects Pershing Square nominees for 2017 annual meeting »

ADP announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

SPX

S&P 500

06:00
08/21/17
08/21
06:00
08/21/17
06:00
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$22.93

-0.1 (-0.43%)

05:59
08/21/17
08/21
05:59
08/21/17
05:59
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$122.30

-0.19 (-0.16%)

05:58
08/21/17
08/21
05:58
08/21/17
05:58
Technical Analysis
SPDR Gold Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUGT

Direxion Gold Miners Bull

$32.21

-0.56 (-1.71%)

05:58
08/21/17
08/21
05:58
08/21/17
05:58
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBR

KBR

$14.92

-0.02 (-0.13%)

05:57
08/21/17
08/21
05:57
08/21/17
05:57
Hot Stocks
KBR awarded PMC contract by OMV Offshore Abu Dhabi GmbH »

KBR announced it has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$18.02

-0.03 (-0.17%)

05:57
08/21/17
08/21
05:57
08/21/17
05:57
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUST

Direxion Daily Gold Miners Bear 3X ETF

$26.95

0.37 (1.39%)

05:57
08/21/17
08/21
05:57
08/21/17
05:57
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$61.01

0.04 (0.07%)

05:57
08/21/17
08/21
05:57
08/21/17
05:57
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VXX

iPath S&P 500 VIX Short-Term Futures

$13.30

-0.36 (-2.64%)

05:55
08/21/17
08/21
05:55
08/21/17
05:55
Technical Analysis
iPath S&P 500 VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XIV

VelocityShares Daily Inverse VIX Short-Term ETN

$73.89

2.39 (3.34%)

05:55
08/21/17
08/21
05:55
08/21/17
05:55
Technical Analysis
VelocityShares Daily Inverse VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TVIX

VelocityShares Daily 2x VIX Short-Term ETN

$21.25

-1.03 (-4.62%)

05:55
08/21/17
08/21
05:55
08/21/17
05:55
Technical Analysis
VelocityShares Daily 2x VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVXY

ProShares Short VIX Short-Term Futures

$70.66

2.42 (3.55%)

05:55
08/21/17
08/21
05:55
08/21/17
05:55
Technical Analysis
ProShares Short VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USO

United States Oil Fund

$9.97

0.35 (3.64%)

05:54
08/21/17
08/21
05:54
08/21/17
05:54
Technical Analysis
United States Oil Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOP

SPDR Oil Exploration and Production Fund

$29.46

0.36 (1.24%)

05:53
08/21/17
08/21
05:53
08/21/17
05:53
Technical Analysis
SPDR Oil Exploration and Production Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$26.11

0.44 (1.71%)

05:53
08/21/17
08/21
05:53
08/21/17
05:53
Technical Analysis
VelocityShares 3x Inv Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UGAZ

VelocityShares 3x Long Natural Gas ETN

$11.73

-0.22 (-1.84%)

05:52
08/21/17
08/21
05:52
08/21/17
05:52
Technical Analysis
VelocityShares 3x Long Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWZ

MSCI Brazil Index

$39.03

0.81 (2.12%)

05:52
08/21/17
08/21
05:52
08/21/17
05:52
Technical Analysis
MSCI Brazil Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFA

iShares MSCI EAFE Index Fund

$66.19

0.18 (0.27%)

05:52
08/21/17
08/21
05:52
08/21/17
05:52
Technical Analysis
iShares MSCI EAFE Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNK

SPDR Barclays High Yield Bond

$36.81

0.03 (0.08%)

05:51
08/21/17
08/21
05:51
08/21/17
05:51
Technical Analysis
SPDR Barclays High Yield Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.